ALBEMARLE WKN: 890167 ISIN: US0126531013 Kürzel: ALB Forum: Aktien Thema: Hauptdiskussion
Albemarle (NYSE:ALB) +1.5% in Wednesday's trading after opening lower following a Berenberg downgrade to Hold from Buy with an $83 price target, slashed from $160, believing the causes behind deteriorating lithium prices will remain persistent in the medium term. "Lower lithium prices have caught Albemarle on the wrong foot and fully committed to a large capex program and may, we think, force the company to raise equity capital," analysts Sebastian Bray and Andres Castanos-Mollor write. European demand for lithium has barely grown and U.S. demand is poor, and the outlook for both markets is negative, the analysts say, with import tariffs being levied and plug-in hybrid vehicles - which have a battery ~20% the size of a full-battery electric vehicle - making sustained market share gains in all markets. Berenberg believes Q2 results will present a "deceptively strong print" by Albemarle (ALB), helped by $100M of profits from an extraordinary sale of disproportionately profitable spodumene from the Greenbushes mine in Australia.
|
Thema | ||
---|---|---|---|
1 | MicroStrategy | -0,69 % | |
2 | News - InnoCan Pharma Aktie | ±0,00 % | |
3 | BTC/USD Hauptdiskussion | +4,61 % | |
4 | CoinBase (Future ExChange) | +0,46 % | |
5 | EVOTEC Hauptdiskussion | ±0,00 % | |
6 | VALNEVA SE Hauptdiskussion | ±0,00 % | |
7 | GAMESTOP Hauptdiskussion | ±0,00 % | |
8 | Canopy Hauptforum | ±0,00 % | |
9 | NVIDIA Hauptdiskussion | -0,14 % | |
10 | Cleanspark Hauptdiskussion | +0,82 % | Alle Diskussionen |
|
Thema | ||
---|---|---|---|
1 | MicroStrategy | -0,69 % | |
2 | News - InnoCan Pharma Aktie | ±0,00 % | |
3 | CoinBase (Future ExChange) | +0,46 % | |
4 | EVOTEC Hauptdiskussion | ±0,00 % | |
5 | VALNEVA SE Hauptdiskussion | ±0,00 % | |
6 | GAMESTOP Hauptdiskussion | ±0,00 % | |
7 | Canopy Hauptforum | ±0,00 % | |
8 | NVIDIA Hauptdiskussion | -0,14 % | |
9 | Cleanspark Hauptdiskussion | +0,82 % | |
10 | DRONESHIELD LTD Hauptdiskussion | ±0,00 % | Alle Diskussionen |